Skip to main content
. 2022 Jun 14;2022:9737587. doi: 10.1155/2022/9737587

Figure 10.

Figure 10

Chemotherapy sensitivity analysis between two risk groups. (a) IC50 of gemcitabine between two risk groups. (b) IC50 of paclitaxel between two risk groups. (c) IC50 of cytarabine between two risk groups. (d) IC50 of doxorubicin between two risk groups.